Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (53 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-03-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Minimum age: 35 (lowers risk) · Who can join
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 44.6% (lowers risk) · Drug's FDA history
• Responsible party: sponsor investigator (raises risk) · Design
• Drug's FAERS reports with a death: 4.2% (lowers risk) · Drug's FDA history
• Primary purpose: prevention (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Design: parallel (raises risk) · Design
• Blinding: triple (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientpatientsbonelargeeligible
  Phrases that lowered it: kgbodymass indexhealthyindex bmi
• Disease area, neurology: No (lowers risk) · Disease area
• Maximum age: 65 (lowers risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty NCT01358669 · started 2011 · scored riskier than 47% of active trials completed
• Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis NCT00980174 · started 2009 · scored riskier than 14% of active trials completed
• A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab NCT01457950 · started 2011 · scored riskier than 11% of active trials completed
• Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy NCT02838121 · started 2009 · scored riskier than 28% of active trials completed
• Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis NCT02114489 · started 2014 · scored riskier than 50% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.